Skip to main content

Table 2 Patient characteristics analyzed in our study (n = 61)

From: Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients

Age, year
 Median 64
 Range 39–84
Sex, n (%)
 Female 44 (72%)
 Male 17 (28%)
Smoking history, n (%)
 Never 44 (72%)
 Former/Current 17 (28%)
ECOG performance status, n (%)
 0–1 52 (85%)
 2–4 9 (15%)
Pretreatment EGFR status, n (%)
 Exon19 deletion 37 (61%)
 Exon21 L858R 19 (31%)
 Other 5 (8%)
EGFR TKI, n (%)
 Gefitinib 49 (80%)
 Erlotinib 7 (12%)
 2nd generation 5 (8%)
  1. Abbreviations: ECOG eastern cooperative oncology group, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor